Exercise may cut the risk of disability from arthritis, a study says. Arthritis is a condition affecting the health of bone joints in the body. People with arthritis are often reluctant to exercise as they fear it will make their condition worse.
Healthy gums may be the key to a healthy heart. A new study has revealed that the treatment of gum disease may reduce the risk of cardiovascular disease.
Obesity has long been linked to heart disease, high blood pressure, and diabetes. Now, researchers are adding kidney failure to the list of ailments, as a new research has found that obese people have up to a seven times greater risk of developing end-stage renal disease, more simply known as kidney failure, than normal weight people.
According to the Arndt Schultz Law, substances vary in action depending on whether the concentration is high, medium, or low. High concentrations kill; medium concentrations suppress or inhibit; and low, or minute concentrations stimulate.
Having a sibling with a history of cardiovascular disease carries the same or greater risk as having a parent with a history of the disease, according to a new report from the long-standing Framingham Heart Study conducted by the National Heart, Lung, and Blood Institute (NHLBI), a part of the National Institutes of Health (NIH). Personal risk of having a cardiovascular event, such as a heart attack, stroke, or peripheral artery disease, may be raised by as much as 45 percent in middle-aged people whose brother or sister has had such an event.
Initial results of the nation’s largest clinical trial for depression have helped clinicians to track ‘real world’ patients who became symptom-free and to identify those who were resistant to the initial treatment. Participants treated in both medical and specialty mental health care settings experienced a remission of symptoms in 12 to 14 weeks during well-monitored treatment with an antidepressant medication. The study, funded by the National Institutes of Health’s (NIH) National Institute of Mental Health (NIMH), used flexible adjustment of dosages based on quick and easy-to-use clinician ratings of symptoms and patient self-ratings of side effects.
The Food and Drug Administration (FDA) has approved the drug Revlimid (lenalidomide) for the treatment of patients with a subtype of Myelodysplastic Syndrome (MDS). The subtype is MDS patients with deletion 5q cytogenetic abnormality.
In a major study funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of the National Institutes of Health (NIH), women with either inactive or stable systemic lupus erythematosus (lupus) – a disease in which the body’s immune system mistakenly attacks and damages healthy tissues of the skin, joints and internal organs – were able to take oral contraceptives without increased risk of flares, or periods of increased disease activity, that characterize the disease.
The Food and Drug Administration (FDA) announced the tentative approval of Stavudine (stav’ yoo deen) for Oral Solution, 1 mg/mL to be manufactured by Aurobindo Pharma LTD. of Hyderabad, India. This product is the first generic version of the already approved Zerit for oral solution manufactured by Bristol-Myers Squibb. This child-friendly product is indicated for use in pediatric patients with HIV, from birth through adolescence. This product will now be available for consideration for purchase under the President’s Emergency Plan for AIDS Relief (PEPFAR).
The U.S. Food & Drug Administration (FDA) approved the use of Tamiflu (oseltamivir phosphate) for prevention (prophylaxis) of seasonal influenza (“flu”) in children 1 to 12 years of age who had close contact with an infected individual. This is the first drug approved for prevention of both influenza A and B in pediatric patients.